Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Relmada Therapeutics (RLMD) Shares Outstanding (Weighted Average) (2016 - 2026)

Relmada Therapeutics has reported Shares Outstanding (Weighted Average) over the past 3 years, most recently at $28.5 million for Q1 2014.

  • Quarterly Shares Outstanding (Weighted Average) rose 21.28% to $28.5 million in Q1 2014 from the year-ago period, while the trailing twelve-month figure was $28.5 million through Feb 2014, up 21.28% year-over-year, with the annual reading at $24.3 million for FY2013, 49.17% up from the prior year.
  • Shares Outstanding (Weighted Average) was $28.5 million for Q1 2014 at Relmada Therapeutics, roughly flat from $28.5 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $28.5 million in Q4 2013 and troughed at $14.1 million in Q2 2012.
  • The 3-year median for Shares Outstanding (Weighted Average) is $23.5 million (2012), against an average of $22.8 million.
  • The largest YoY upside for Shares Outstanding (Weighted Average) was 66.63% in 2013 against a maximum downside of 21.28% in 2013.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $23.5 million in 2012, then rose by 21.28% to $28.5 million in 2013, then changed by 0.0% to $28.5 million in 2014.
  • Per Business Quant, the three most recent readings for RLMD's Shares Outstanding (Weighted Average) are $28.5 million (Q1 2014), $28.5 million (Q4 2013), and $24.3 million (Q3 2013).